Engineered immune cells take on tough T-Cell cancers in new trial
NCT ID NCT07244380
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new treatment called S101 CAR-T cells for people with a type of T-cell cancer (T-LBL/ALL) that has come back or not responded to standard therapy. The treatment uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells. The main goal is to see if the cancer shrinks or disappears three months after treatment. About 38 participants will be enrolled.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T LYMPHOBLASTIC LEUKEMIA/LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Stem cell showdown: which transplant best keeps T-Cell cancer at bay?
- New combo therapy aims to beat tough blood cancer
- New maintenance therapy shows promise in preventing T-Cell cancer relapse after transplant
- Engineered immune cells take aim at stubborn leukemia after transplant
- Engineered immune cells take on tough blood cancers in early trial
- Experimental combo aims to boost stem cell transplant for rare blood cancers